Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
700.33
+4.31 (0.62%)
Feb 21, 2025, 4:00 PM EST - Market closed
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$940,156
Profits / Employee
$292,109
Market Cap
74.95B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | 8,100 | 700 | 9.46% |
Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
Dec 31, 2017 | 6,200 | 800 | 14.81% |
Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
Dec 31, 2014 | 2,925 | 585 | 25.00% |
Dec 31, 2013 | 2,340 | 390 | 20.00% |
Dec 31, 2012 | 1,950 | 246 | 14.44% |
Dec 31, 2011 | 1,704 | 309 | 22.15% |
Dec 31, 2010 | 1,395 | 366 | 35.57% |
Dec 31, 2009 | 1,029 | 110 | 11.97% |
Dec 31, 2008 | 919 | 237 | 34.75% |
Dec 31, 2007 | 682 | 109 | 19.02% |
Dec 31, 2006 | 573 | -15 | -2.55% |
Dec 31, 2005 | 588 | -142 | -19.45% |
Dec 31, 2004 | 730 | 86 | 13.35% |
Dec 31, 2003 | 644 | -25 | -3.74% |
Dec 31, 2002 | 669 | 94 | 16.35% |
Dec 31, 2001 | 575 | 84 | 17.11% |
Dec 31, 2000 | 491 | 54 | 12.36% |
Dec 31, 1999 | 437 | 66 | 17.79% |
Dec 31, 1998 | 371 | 101 | 37.41% |
Dec 31, 1997 | 270 | 27 | 11.11% |
Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
REGN News
- 20 hours ago - Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman - GlobeNewsWire
- 3 days ago - REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025 - GlobeNewsWire
- 3 days ago - Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman - Accesswire
- 4 days ago - Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) - GlobeNewsWire
- 5 days ago - Why Regeneron's Price May Soon Break Out - Seeking Alpha
- 6 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - Accesswire
- 7 days ago - Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman - GlobeNewsWire
- 10 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire